Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Tesla Raises Cybertruck Prices by $5,000 in US 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Trump Buys SpaceX Shares After Record IPO 
Add as a preferred source on Google
DUBLIN, April 20, 2018 -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2018 on Tuesday, May 1, 2018. The Company has scheduled a conference call for that same day, Tuesday, May 1, 2018 at 11:00am ET (4:00pm BST) to discuss the results of the quarter.
Interested parties can access the call by dialing:
| USA: | 1-844-861-5499 |
| International: | 1-412-317-6581 |
| Conference ID #: | 10119605 |
A simultaneous webcast of the call can be accessed at:
https://www.webcaster4.com/Webcast/Page/1135/25538
A replay of the call can be accessed until May 8, 2018 by dialing:
| USA: | 1-877-344-7529 |
| International: | 1-412-317-0088 |
| Conference ID #: | 10119605 |
The webcast of the call will be available for 30 days at:
https://www.webcaster4.com/Webcast/Page/1135/25538
Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.
Contact
Kevin Tansley
Trinity Biotech plc
(353)-1-2769800
E-mail: [email protected]
Joe Diaz, Joe Dorame and Robert Blum
Lytham Partners, LLC
Investor Relations
602-889-9700
